Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020
Paris (France), December 10, 2020 – 6 pm CET – Onxeo S.A. (ISIN: FR0010095596), (“Onxeo” or “the Company”), a clinical-stage […]
Onxeo announces a capital increase of €7.3 million by private placement to Invus and Financière de la Montagne, the Company’s historical shareholder
The funds raised will accelerate the development of Onxeo’s programs, and extend its cash runway into Q1 2022 Paris […]
Onxeo launches a capital increase by means of an accelerated book-build offering
Paris (France), June 19, 2017 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the […]
Onxeo successfully raises €15 Million with US and European investors
Offering upsized in response to investor demand Paris (France), June 20, 2017 – 08:00 am CEST – Onxeo S.A. […]
Onxeo announces the great success of its share capital increase with shareholders’ preferential subscription rights
Total demand of Approximately 76.4 million euros, i.e. an oversubscription rate of 216% of the offer Full exercise of the […]
Onxeo announces closing of DNA Therapeutics acquisition
Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq […]
Onxeo renews its equity financing line with Nice & Green as part of the financing of its business and strategic activities
The new financing line could represent a total of approximately €9 million over the upcoming 12 months, based on current […]
BioAlliance Pharma and Topotarget enter into merger agreement to create a leading orphan oncology company
— Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical […]
Definitive Merger Plan between BioAlliance Pharma and Topotarget – Combined Entity to be named Onxeo
DEFINITIVE MERGER PLAN BETWEEN BIOALLIANCE PHARMA AND TOPOTARGET COMBINED ENTITY TO BE NAMED ONXEO — Onxeo expected to have a […]
Registration of “Document E” and clearance of admission prospectus related to the proposed cross-border of Topotarget into BioAlliance Pharma
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
Merger Plan with Topotarget: Pre-approval for the secondary listing of the shares of the merged company on NASDAQ OMX Copenhagen
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma and Topotarget shareholders approve proposed cross-border merger to create Onxeo
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specializing in the development of drugs for orphan oncology diseases, […]
BioAlliance Pharma strengthens its financial resources with the support of its top shareholder
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014 – Final calendar for trading on both Euronext and NASDAQ OMX to be available soon
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, […]
Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen, Merger exchange to take place on August 5, 2014
Suite à l’annonce conjointe des deux sociétés le 23 juillet 2014, BioAlliance Pharma SA (Euronext Paris – BIO), société innovante […]
Onxeo Launches a Rights Issue With Shareholder Preferential Subscription Rights, for a Maximum Amount of up to €41.6 Million (Including an Extension Clause of €5.3 Million)
Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”), an innovative biopharmaceutical company specialized in the development […]
Onxeo announces acquisition of DNA Therapeutics and provides update on Validive® development plan
Onxeo acquires first-in-class, signal-interfering DNA molecule based on one of the most promising new approaches in cancer treatment Acquisition expands […]
Onxeo Launches Capital Increase
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), a biopharmaceutical company specializing in […]
Onxeo Raises €12.5 Million through Capital Increase with US and European Investors
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), a biopharmaceutical company specializing in […]
Onxeo Implements an Equity Line Financing Including an Incentive Program with Nice & Green SA
Cash for Operations Extended to Q3 2020 Paris (France), June 15, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext […]